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ABSTRACT 
 
 
COVALENTLY FUNCTIONALIZED MSNS AS POTENTIAL 
PHOTOSENSITIZING AGENTS FOR PDT 
 
 
 
Merve TürkĢanlı 
M.S. in Materials Science and Nanotechnology 
Supervisor: Prof. Dr. Engin U. Akkaya 
January, 2011 
 
 
Photodynamic therapy (PDT) is a novel approach for the treatment of some cancers 
and other non-malignant diseases. PDT aims to kill cancer tissue by the generation 
of singlet oxygen as a result of excitation of the photosensitizer (PS) by illuminating 
with a light source at a certain wavelength. Mesoporous silica nanoparticles are 
promising in PDT issue due to their chemical inertness, biocompatibility, low-
toxicity, hydrophility and ease of surface modification. We have synthesized and 
characterized novel boradiazaindacene (BODIPY)-based PS that is covalently 
attached to the pore of mesoporous silica nanoparticles (MSNs). We have observed 
that near infrared absorbing photosensitizer attached MSNs successfully generate 
cytotoxic singlet oxygen. 
 
Keywords: Boradiazaindacene, photodynamic therapy, photosensitizer, mesoporous 
silica nanoparticles, drug carrier system. 
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ÖZET 
 
 
 
FOTODĠNAMĠK TERAPĠ ĠÇĠN POTANSĠYEL 
FOTODUYARLAġTIRICI NITELIĞI OLAN, KOVALENT OLARAK 
TÜREVLENDĠRĠLMĠġ MEZO GÖZENEKLĠ SĠLĠKA 
NANOPARÇACIKLAR  
  
 
 
Merve TürkĢanlı 
Malzeme Bilimi ve Nanoteknoloji Programı, Yüksek Lisans 
Tez Yöneticisi: Prof. Dr. Engin U. Akkaya 
Ocak, 2011 
 
 
Fotodinamik terapi, bazı kanser ve kötü huylu olmayan hastalıkların tedavisi için 
geliĢtirilmiĢ yeni bir yaklaĢımdır. Fotodinamik terapi, fotouyarıcının belirli bir 
dalga boyuna sahip ıĢık kaynağı tarafından uyarılmasının ardından sitotoksik singlet 
oksijen oluĢturması ile kanserli dokunun öldürülmesini amaçlar. Mezo gözenekli 
silika nanoparçacıklar sahip oldukları kimyasal inertlik, biyouyumluluk, düĢük 
toksisite, hidrofilite ve yüzey modifikasyonunun kolaylığı özellikleri sebebiyle 
fotodinamik terapi konusunda ümit verici bir yaklaĢımdır. Bu çalıĢmada, yeni 
BODIPY temelli fotoduyarlaĢtırıcı sentezlendi ve karakterize edildi. Bu 
fotoduyarlaĢtırıcı, mezo gözenekli silika nanoparçacık gözeneğine kovalent olarak 
bağlanmıĢtır. Yakın kızılötesi bölgede soğuran fotoduyarlaĢtırıcının nanoparçacığa 
bağlanması sonucu baĢarılı bir Ģekilde singlet oksijen oluĢturduğu gözlemlenmiĢtir.  
 
Anahtar Kelimeler: Boradiazaindasen, fotodinamik terapi, fotosensitizör, mezo 
gözenekli silika nanoparçacık, ilaç taĢıma sistemi. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
1.1 Photodynamic Therapy 
 
Photodynamic therapy is a novel, promising approach for the treatment of some 
cancers and other non-malignant diseases. The therapy involves two important 
stages; administration of a photosensitizer and illumination of the tissue to activate 
the photosensitizer with the light of a specific wavelength. When the tissue is 
illuminated, the photosensitizer which previously localized at the tumor is excited. 
The excitation of the molecule leads to several molecular energy transfers and 
finally highly reactive and cytotoxic oxygen species called singlet oxygen (
1
O2) is 
produced 
1
. In biological systems, 
1
O2 has a lifetime of <0,04 microsecond 
2
. During 
this very short interval,  
1
O2 species causes cancer cells damaged or destroyed either 
targeting the cells directly, causing necrosis and/or apoptosis
3 
or by targeting 
tumour or healthy surrounding vasculature 
4
. 
PDT has numerous advantages over the traditional treatment methods of cancer 
such as surgery, radiotherapy and chemotherapy. Firstly, targeting is achieved by 
the delivery of the light. At a certain time after the administration of the drug, light 
is targeted into the tumour and surrounding vasculatory by fiber optic systems and 
endoscopy. This in turn, causes only damage of tumours. Since the life time of 
1
O2 
2 
 
species is very short, it migrates less than 0.02 µm after its generation5 . As a result 
it is deactivated before it can flee out of the cell. 
Secondly, the tumours have abnormal physiology such as; leaks at vasculatory, 
lower pH value, higher number of low density protein receptors, presence of 
macrophages, larger amount of lipids
2
. The photosensitizers which are developed 
for these environments achieve selectivity. On the other hand, limitation of PDT 
rises because of the fact that it cannot treat the advanced disseminated diseases 
since the illumination of the entire body and the uptaken of the appropriate doses of 
drug is impossible.  
As a result, for localized tumours or the early stages of the disease, PDT is a 
selective and usefull therapy with many advantages and for the advanced level of 
the disease, it improves the life quality and improves survival time.  
 
1.1.1 History of Photodynamic Therapy  
 
Light has been used as a therapeutic agent since ancient ages. However, in 
medicine and surgery, it is being used just with the beginning of the last century. 
Ancient Egypt, China and India took the advantage of light to treat some skin 
diseases, such as psoriasis, vitiligo and cancer 
6
. In ancient Greek, the whole body 
was exposed to sunlight to treat diseases. This way of therapy was called as 
heliotherapy by the famous Greek physician Heredotus
7
. Danish physician Niels 
Finsen used UV light and carbon arc phototherapy for the treatment of cutaneous 
tuberculosis. With that study, Finsen got Nobel Prize in 1903 
7,8
.
 
 
The use of light as a therapy is called as phototherapy, on the other hand, in 
addition to phototherapy when the photosensitizers are used, the treatment way is 
3 
 
called photochemotherapy. Photochemotherapy also has a history of 3000 years. 
Indians first employed psoralens with light to treat vitiligo 
9
. 
Photodynamic therapy, acquiring cell death by the use of photosensitizer with a 
light, has been familiar for 100 years. First medical application of photodynamic 
therapy in literature was done by von Tappeiner and a dermatologist named 
Jesionek. They used topical eosin and white light for the treatment of skin cancer
10
. 
The requirement of oxygen in the reaction environment for the therapy was firstly 
introduced by Jodlbauer and von Tappeiner in 1907 and they entitled this 
phenomenon as “photodynamic action”11.  
In 1911, Hausmann reported the effect of hematoporphyrin and light on a 
paramecium and red blood cells of a mice
12
. Friedrich Meyer-Betz injected himself 
hematoporphyrin and exposed himself to light in order to observe the effects on 
humans as well as mice and he noticed long term pain at the areas where light has 
been exposed
13
. In 1978, with a 25 skin cancer patients were treated with PDT by 
Dougherty and this was the first clinical study which proved PDT can be used for 
the treatment of some malignant cancers more successfully than the conventional 
therapies
14
.  
Over the years PDT has been used successfully for the treatment of some other 
types of tumor such as, bladder cancer
15
, brain tumors
16
, head and neck tumors
17
, 
rectal cancer
18
, gynecological tumors
19
. 
 
1.1.2. Working Mechanism of Photodynamic Therapy 
 
The activation of the photosensitizer with an appropriate wavelength of a light 
initiates the series of energy transfers. When the photosensitizer absorbs the light, it 
transfers from ground singlet state (
1
PS) into its excited singlet state (
1
PS*). 
1
PS* 
4 
 
may either return back to ground state by fluorescence directly or it undergo 
electron spin conversion to its triplet state (
3
PS*) which is needed to initiate 
photodynamic action. 
3
PS* may undergo two different reaction types in the 
presence of O2. In reaction Type I; the excited molecules transfer electron or proton 
to substrates and produce radicals or radical ions. Alternativeley in reaction Type II; 
excited photosensitizer transfers its energy to oxygen and cytotoxic singlet oxygen 
species (
1
O2) is produced
20
.       
1PS 1PS*
1O2
Radical 
ions
radicals
+ O2
+ substrate
1PS
3PS*
TYPE I Reaction
TYPE II Reaction
FLUORESCENSE
Figure 1. The principle of photodynamic therapy.  
There are three different pathways that all come to the same result which is 
tumor death. 
1
O2 , which is generated by the series of photochemical reactions, may 
kill directly the tumor cells by inducing apoptosis and/or necrosis. It may also 
damage the vasculatory that surrounds the tumor and kill the tumor cells 
5 
 
indirectly
21
. In addition, after PDT treatment, the immune system is induced
22
. As a 
result, the immune response is initiated to kill the remaining tumor cells. 
The vascular response, to kill the surrounding vasculatory of the tumor and 
making the tumor starving of oxygen and nutrients
23
, is important however, 
researchers pay attention more to the effects of PDT in cellular level. The target 
sites of the cellular level include mitochondria, the plasma membrane, nuclei and 
lyzozomes
24
. The effectiveness of PDT is mainly resulted from the apoptotic 
response in cells. Apoptosis is programmed cell death due to the change of the 
biochemical environment of the cell. The mitochondrial damage is of top priority 
which leads to apoptosis 
21, 25
. 
 
1.1.3. Photosensitizing Agents 
 
The most ideal photosensitizing agents would have the properties such as, 
biostability, photochemically efficient (having a strong absorption peak at 
wavelengths >630nm), selective to target tissue (retain at the target tissue relatively 
more than normal surrounding tissues), minimum toxicity at the healthy parts of the 
body.  
Photobleaching, destruction of the fluorescent molecules due to the generation 
of singlet oxygen species during the photodynamic action, is one of the main 
problems of photosensitizers
26
. As a result, photosensitizers must be 
photochemically stable.  
Light penetration depth of the human tissue limits in the range of 620-850 nm 
because of the absorption properties of the medium
27
 (Fig.2). This limited light 
penetration range is called as therapeutic window of the body. The photosenstizers 
must have a strong absorption in the region of the therapeutic window, thus they 
6 
 
can transfer their energy to oxygen in order to produce cytotoxic singlet oxygen 
species
28
 .   
 
 
1.1.3.1 Clinical Studies of Photosensitizing Agents 
 
Photofrin (porfimer sodium, Axcan Pharma, Montreal, Canada), a complex 
mixture of hematoporphyrin derivatives, is the first drug that was approved for 
PDT
7
. Since photofrin is very effective in terms of; killing the tumor, non-toxic 
when there is no illumination and water soluble, it is the most common 
photosensitizer for the treatment of some tumors other than dermatological. The 
cancers that are treated with photofrin are, early stage lung cancers, cervical cancer, 
bladder cancer, gastric cancer and oesophageal adenocarcinoma
28
. 
Figure 2. The optical absorption of various tissue components and therapautic window of 
body. 
7 
 
Although porfimer sodium is effective, it has several disadvantages which are 
improved in subsequent photosensitizers. The selectivity of the drug between 
tumors and healthy tissues is low
29
. After the administration of the porfimer sodium 
there should be waiting period of 48-72h before the illumination and since the drug 
causes skin photosensitivity during this period of time patient must be protected 
from light
30
. 
Research has been done to develop new photosensitizers which have improved 
properties over photofrin. Table 1 shows the approved photosensitizers and type of 
cancer they are applied. 
  
Table 1. Type of cancer and approved drug
20
 
 
TYPE OF CANCER PHOTOSENSITIZER COUNTRY 
Actinic keratosis ALA (Levulan, Metvix)   U.S., EU 
Basal Cell Carcinoma ALA (Metvix) EU 
Barrett’s HGD Porfimer sodium   U.S., Canada, EU, UK 
Cervical Cancer Porfimer sodium   Japan 
Endobronchial Cancer Porfimer sodium   Canada, UK,US,EU 
Esophageal Cancer Porfimer sodium   Canada, UK,US,EU 
Gastric Cancer Porfimer sodium   Japan 
Head and Neck Cancer Foscan EU, Norway, Iceland 
Papillary bladder Cancer Porfimer sodium   Canada 
Abbreviations: ALA, 5-aminolevulinic acid, HGD, high-grade dysplasia 
8 
 
 
The generality of photosensitizers in literature are hematoporphyrin derivatives. 
The structures of some photosensitizers in literature and their absorption 
wavelengths within the therapeutic window are given below (see Figure 2.)   
 
Porphyrin derivatives 
 
 
 
Phthalocyanines and naphtalocyanines 
 
                             
 
Hematoporphyrin 
(Photofrin), 630nm 
Phatalocyanine, 700nm Naphthalocyanine, 780nm 
9 
 
Texapyrins      Chlorins and Bacteriochlorins 
                                     
 
Aza dipyrromethene dyes 
                 
 
Perylenediimide dyes     Boron dipyrromethene dyes 
          
Figure 3. Structures of some photosensitizers in literature. 
m-THPC,(Foscan), 650nm Texaphyrinato-Lu(III), 600-
900nm 
Aza dipyrromethene dyes, 
650nm 
10 
 
1.1.3.2 Boron dipyrromethene (BODIPY) dyes 
 
4,4-Difluoro-4-bora-3a,4a-diaza-s-indacene (abbreviated to BODIPY) dyes are 
novel photosensitizers with the properties of high extinction coefficients, high 
quantum efficiencies of fluorescence and stability in physiological environment
31
. 
Possessing these advantageous properties, BODIPY dyes have become attractive in 
PDT research. One important point that draws interest on BODIPY dyes being able 
to modify them easily by attaching functional groups that can increase the 
selectivity of the dye to the target site. As they are used in imaging technologies by 
labeling proteins
32
 and DNA
33
 by the modifications on dye, they are used in PDT 
with increased targeting to tumor tissue
34
. In addition to targeting, one more 
advantage arises with the modification of the BODIPY dyes which is red shift in the 
absorption wavelength. Akkaya et al. synthesized four different styryl BODIPY 
dyes by stopping the reaction at appropriate time and observed the absorption and 
emission wavelength shifts successfully
35
.  
 
Figure 4.  One-pot synthesis of different styryl BODIP dyes
35
. 
11 
 
 
Figure 5. Absorption and emission spectra of styryl BODIPY dyes
35
. 
 
 
 
 
Figure  6. BODIPY- based photosensitizers in literature. Compound 1 is the first BODIPY-
based photosensitizrs reported by Nagano et al., compound 2 and 3 were reported by Akkaya et 
al.35, 36, 34 
 
The study of Akkaya et al.
34 
is an important example of the modification of 
BODIPY for the tumor tissue environment. As it is previously discussed, tumor 
12 
 
tissues have abnormal physiological properties such as low pH, high concentration 
of Na
+
 ion. The photosensitizer that was synthesized by Akkaya et al. (compound 3 
in fig. 6) has two different functional groups which are sensitive to acidicity and 
sodium ion concentration. In the acidic medium, pyridine groups are protonated and 
red shift occurs from 630 nm to 660 nm. Thus, only the protonated molecules 
would absorb light at 660 nm. In the absence of sodium ion, photo induced electron 
transfer (PET) occurs however when the sodium ion concentration increases, 
sodium ion binds to crown ether group of the molecule and PET is blocked. By this 
way, only in the tumor tissues where the two parameters are above a threshold 
value, the 
1
O2 species would be generated. (Fig. 7)  
 
 
 
Figure 7. Smart photosensitizer that is selective to tumor tissue environment
34
.  
 
13 
 
1.1.4. Light Sources 
 
 
For the activation of photosensitizers, conventional arc lamps can be used. They 
are cheap and easy to use, however they are broad spectrum light sources so filters 
should be used to cut off UV and IR emission to avoid heating. In addition, while 
coupling them to light delivery fibers, there occurs optical power loss. Thus, it is 
not efficient to use arc lamps clinically.  
The development of lasers is an important breakthrough in PDT because early 
lasers were expensive, large and cannot removable and expertise is needed to use 
them.  The development in semiconductor lasers results in cheaper, mobile systems 
that can be used corporately with optical fiber technology. For PDT to be 
successful, the light should be delivered from source to target homogenously, thus 
the optical fibers provide the needs for illumination at different localization.  
Light emitting diodes (LEDs) can also be used clinically. They are small, 
cheaper than the other light sources and provide a power output up to 150mW/cm
2 
at wavelengths between 350-1100 nm
37
.    
1.2 Requirements for Drug Delivery Systems 
 
 
Over the last decades, many organic dyes, porphyrin derivatives and other 
biomolecules have been synthesized as photosensitizing agents. However, 
developments in photosensitizing agents yet could not solve all the problems for the 
clinical applications.  
14 
 
First of all, most of the photosensitizing agents are hydrophobic so they are 
water insoluble molecules. Thus, in aqueous media they aggregate easily which in 
turn results in two important issues, decrease in quantum efficiency and severity at 
injection through the body.  
  Secondly, to prevent the damage of healthy tissues selective accumulation of 
photosensitizing agent is required. Although, recently photosensitizers are 
synthesized in order to increase selective targeting, they are still not selective 
enough to be applied clinically.  
As a result, the construction of stable and effective photosensitive agent carriers 
become vital and play an important role for the development of PDT. The common 
examples of delivery agents are liposomes, oil dispersions, low-density lipoproteins 
and nanoparticles
38,39
.  
1.2.1 Nanoparticles as photosensitizer carriers for PDT 
 
 
Recently, nanotechnology focuses on development of nanoparticles as 
photosensitizer carriers. Nanomaterials are promising in PDT issue because (1) they 
could be made water soluble, i.e. hydrophilic, (2) they have large surface areas 
which can be modified with functional groups, thus gain selectivity for the tumor 
tissue, (3) they have sub-cellular size so they can easily penetrate deeper into the 
tissue and are efficiently taken up by the cell. 
PS agent could be encapsulated within their matrix, adsorbed on the material or 
conjugated on the surface. Since the surface of these nanoparticles is ready for 
modification, tumor seeking sites can be attached to the surface of them which 
provides specific targeting. In addition, attachment of a different fluorescent 
molecule provides biological imaging of the system.   
15 
 
There are various types of nanomaterials that can be used as PS carrier systems, 
organic compounds, inorganic oxides, metal compounds.    
        
1.3. Mesoporous silica nanoparticles (MSNs) as PS carrier 
 
 
Research on ceramic based nanomaterials as a drug carrier system for PDT has 
been done recently. Synthesis of organically modified silica nanoparticles 
(ORMOSIL) was first reported by Ohulchanskyy et al. According to Ohulchanskyy 
and his colleagues, this novel nanoparticles consist of silica nanoparticles and 
covalently incorporated photosensitizer HPPH (2-devinyl-2-(1-
hexyloxyethyl)pyropheophorbide) for PDT
40 
. Zhang et al. reported photosensitizer 
carrier system for PDT in which PS absorbs infrared light based on photon 
upconverting nanoparticles (PUNPs) coated with silica matrix
41
.  
During the last decade, research has done to develop mesoporous materials. 
Possessing the good properties such as being chemically inert, thermally stable in 
biological environment, harmless for human body and inexpensive, silica is the well 
developed mesoporous material
42
.  
Mesoporous silica particles were first described and patented by French 
scientists in 1967
43
; however it was not noticed until 1990’s. In 1989 Kato et al. 
reported microporous silica particles which were synthesized by using kanemite as 
starting material
44
. In 1992, Kresge et al. firstly introduced MCM-41, mesoporous 
crystalline materials, at Mobil Research and Development Corporation 
Laboratories
45
. Following this study, there were a few achievements which mainly 
introduced new types of mesoporous silica nanoparticles with different pore size 
distributions
46,47
.   
16 
 
There are many procedures to synthesize different size and pore distribution 
MCM series. The most commonly used synthesis pathway is the organic template 
driven one
48
. A template is an agent which directs a structure. It is often a molecule 
or ion around which a framework is built. They are used for the synthesis of large 
number of zeolites and the most common ones are quaternary ammonium ions with 
a short alky chains. For the synthesis of MCM-41, quaternary ammonium ions with 
a long alkyl chain, generally hexadecyl group, are used as a template. In aqueous 
media, the long hydrophobic alkyl chain of the template would aggregate in order to 
minimize the interaction of the hydrophobic chain with highly polar water 
molecules. This aggregation results in the formation of micelles. These micelles 
have hydrophilic surface due to the ionic character of ammonium and hydrophobic 
core consists of large alkyl chains. In order to minimize the surface energy, micelles 
tend to form a spherical shape. However, as the number of templates increase in 
aqueous media, micelles evolved into different geometry. These micelles have new 
shape of long tubes, often denoted as rod-like micelles. When the concentration of 
templates even becomes higher, they aggregate and form hexagonal liquid 
crystalline structure which resembles the MCM-41 structure
49
.  
 
Figure 8. Synthesis pathway of MCM-41
46 
. 
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CHAPTER 2 
 
EXPERIMENTAL PROCEDURES 
 
2.1 General 
 
 
All chemicals and solvents purchased from Sigma-Aldrich and they were used 
without further purification. 
1
H NMR and 
13
C NMR data were obtained using 
Bruker DPX-400 in CDCl3 with TMS as internal reference. Splittings in spectra are 
shown as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Column 
chromatography for all products was performed by using Merck Silica Gel 60 
(particle size: 0.040- 0.063 mm, 230-400 mesh ASTM).  
Mass spectrometry was performed using MS-QTOF at Bilkent University, 
UNAM, Mass Spectrometry Facility.  
Absorption spectrometry was performed using Varian UV-Vis-NIR 
Spectrophotometer. Fluorescence emission spectra were obtained by using Varian 
Eclipse spectrofluorometer.   
Particle size and zeta potential data were acquired by using Malvern Zetasizer 
Nanoseries at Bilkent University, UNAM, Ankara.  
XRD data were obtained by using PANalytical X’Pert Pro MPD Multi-purpose 
X-ray diffractometer at Bilkent University, UNAM, Ankara.  
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SEM images were acquired in UNAM, Ankara, using Quanta 200 FEG, 
Environmental Scanning Electron Microscopy. TEM images were obtained in 
UNAM, Ankara, using FEI Technai G2 F30 high resolution transmission electron 
microscope and carbon grid.  
Analysis of Nitrogen Adsorption was done at METU, Central Laboratory, 
Surface Characterization Unit, Ankara, by using Quantachrome Corporation, 
Autosorb-6.     
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2.2 Synthesis of Photosensitizer 
 
2.2.1 Synthesis of 4-(3-bromopropoxy)benzaldehyde (3)  
 
 
Figure 9. Synthesis of compound 3 
 
Hydroxybenzaldehyde (2 g, 16.4 mmol) and 1,6 dibromohexane (5.2 ml, 32.8 
mmol) were dissolved in acetonitrile (150ml). K2CO3 (6.88 g, 49.2 mmol) and a few 
crystals of 18-crown-6 were added. The reaction mixture was refluxed for 48 h. 
Then acetonitrile was evaporated in vacuum and extracted with water and 
chloroform. Organic phase was dried with Na2SO4 and evaporated by using rotary 
evaporator. The product was purified by silica gel column chromatography using 
CHCl3/Hexane (5:1, v/v). Fraction containing product 3 was collected then the 
solvent was removed by using rotary evaporator. (2.4 g, 8.4 mmol, 51%). 
 
1
H NMR (CDCl3, 400MHz, δ ppm) 1.45 (m, 4H), 1.75 (t, J= 6.7Hz, 2H), 1.82 (t, J= 
6.9Hz, 2H), 3.32 (t, J= 6.7Hz, 2H), 3.95 (t, J= 6.4Hz, 2H), 6.89 (d, J= 8.8Hz, 2H), 
7.73(d, J= 8.7Hz,2H), 9.80 (s,1H) 
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2.2.2 Synthesis of 4-(3-azidopropoxy)benzaldeyhde  (4) 
 
 
 
Figure 10. Synthesis of compound 4 
 
 
4-(3-Bromopropoxy)benzaldehyde (3, 1.5 g, 5.3 mmol ) was dissolved in 
DMSO (25ml), NaN3 ( 1.37 g, 21.2 mmol) was added. Reaction mixture was heated 
to 60
o
C for 3 hours. Extraction was done several times with water and chloroform 
to get rid of DMSO. After the extraction, organic phase was dried with Na2SO4 and 
evaporated by using rotary evaporator. The residual compound was liquid at room 
temperature and pure.    
 
1
H NMR (CDCl3, 400MHz, δ ppm) 1.30-1.45 (m, 4H), 1.55 (t, J= 6.4Hz, 2H), 1.72 
(t, J= 6.5Hz, 2H), 3.20 (t, J= 6.9Hz, 2H), 3.95 (t, J= 6.4Hz, 2H), 6.90 (d, J= 8.7Hz, 
2H), 7.72 (d, J= 8.9Hz, 2H), 9.75 (s, 1H) 
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2.2.3 Synthesis of 8-(4-(6-azidohexyloxy)phenyl)-1,3,5,7-
tetramethyl-BODIPY (5) 
 
 
 
Figure 11. Synthesis of compound 5 
 
CH2Cl2 (200 ml) was purged with Ar for 20 minutes. 4-(3-
azidopropoxy)benzaldeyhde 4 ( 0.7 g, 2.85 mmol) and 2,4-dimethyl pyrrole (0.65 g, 
5.7 mmol) were added. 3 Drops of trifluoroacetic acid was added and the color of 
reaction mixture was turned into red. The reaction mixture was stirred at room 
temperature for 12h. Then tetrachloro-1,4-benzoquinone (0.7 g, 2.65 mmol) was 
added ant the reaction mixture stirred at room temperature for 45 min. Then triethyl 
amine (3 ml) and borontrifluoride diethyl etherate were added respectively. After 
stirring at room temperature for 45 minutes, extraction was done with water. 
Organic phase was dried with Na2SO4 and evaporated by using rotary evaporator. 
The purification was done by silica gel column by using chloroform. Fraction that 
contains compound 5 was collected then the solvent was evaporated by using rotary 
evaporator. (0.69 mmol, 25%).  
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1
H NMR (CDCl3, 400MHz, δ ppm) 1.42 (s, 6H), 0.45-1.62 (m, 4H), 1.65 (t, J= 7.2, 
2H), 1.85 (t, J= 7.3, 2H), 2.55 (s, 6H), 3.30 (t, J= 6.8, 2H), 4.03 (t, J= 6.4, 2H), 6.00 
(s, 2H), 7.00 (d, J= 4.6), 7.18 (d, J= 4.6) 
13
C NMR (CDCl3, 100MHz, δ ppm) 14.6, 25.7, 26.6, 28.8, 29.1, 51.4, 67.9, 115.0, 
121.2, 126.8, 129.2, 130.4, 131.8, 141.9, 143.2, 155.2, 159.6 
HRMS-ESI: calculated for M+H 466.3464, found 466.2573, ∆m= 19 ppm 
 
2.2.4 Synthesis of 8-(4-(6-azidohexyloxy)phenyl)-2,6-
dibromo1,3,5,7-tetramethyl-BODIPY (6) 
 
 
 
Figure 12. Synthesis of compound 6 
 
10-(4-(6-azidohexyloxy)phenyl)-2-8-dibromo-5,5-difluoro-1,3,7,9-tetramethyl-
5H-dipyrrolo[1,2-c:1',2'-f] [1,3,2]diazaborinin-4-ium-5-uide 6 (322 mg, 0.69 mmol) 
was dissolved in a mixture of DMF/DCM (25ml:25ml). Then N-bromo succinimide 
(370 mg, 2.07 mmol) was dissolved in DCM (25ml). NBS in DCM solution was 
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added to the reaction solution dropwise in 15 min. The reaction mixture was stirred 
at room temperature for 2 hours. Followed by thin layer chromatography the 
reaction was stopped and the extraction was done with water and DCM. The 
organic phase was dried with Na2SO4 and evaporated by using rotary evaporator. 
The purification was done by silica gel column by using chloroform/ hexane 
mixture (3:1 v/v). Fraction that contains compound 6 was collected then the solvent 
was evaporated by using rotary evaporator. (150 mg, 0.239 mmol, 35%) 
 
 
1
H NMR (CDCl3, 400MHz, δ ppm) 1.42 (s, 6H), 1.45-1.62 (m, 4H), 1.65 (t, J= 7.2, 
2H), 1.85 (t, J= 7.3, 2H), 2.60 (s, 6H), 3.30 (t, J= 6.8, 2H), 4.03 (t, J= 6.4, 2H), 7.00 
(d, J= 4.6, 2H), 7.18 (d, J= 4.6, 2H) 
13
C NMR (CDCl3, 100MHz, δ ppm) 13.7, 13.9, 25.7, 26.3, 27.0, 28.8, 29.1, 51.4, 
68.0, 115.3, 126.3, 129.1, 130.8, 140.6, 142.4, 153.7, 160.1 
HRMS- ESI: calculated for M+H 622.07, found 622.0727 ∆m= 4.3 ppm 
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2.2.5 Synthesis of compound 7 
 
 
 
Figure 13. Synthesis of compound 7 
 
Compound 6 (100 mg, 0.160 mmol) and 4-methoxybenzaldehyde (55mg, 0.40 
mmol) dissolved in benzene (50 ml). Piperidine (0.4 ml) and glacial acetic acid (0.4 
ml) were added respectively. The solution was refluxed by using Dean-Stark 
apparatus. When the amount of solvent remained in the solution was minimized, the 
reaction was followed by TLC until observing the green colored product had the 
major band. Then the reaction was stopped and the extraction was done with 
chloroform and water. The organic phase was dried with Na2SO4 and evaporated by 
using rotary evaporator. The purification was done by silica gel column by using 
chloroform as mobile phase. Fraction containing compound 7 was collected then 
the solvent was evaporated under reduced pressure. (90 mg, 0.105 mmol, % 66) 
1
H NMR (CDCl3, 400MHz, δ ppm) 1.50 (m, 4H), 1.50 (s, 6H), 1.65 (t, J= 7.1 Hz, 
2H), 1.90 (t, J= 7.2, 2H), 3.30 (t, J= 6.8, 2H), 3.88 (s, 6H),  4.08 (t, J= 6.3, 2H), 
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6.95 (d, J= 8.8, 4H), 7.04 (d, J= 8.6, 2H), 7.19 (d, J= 8.6, 2H), 7.65 (m, 2H+4H), 
8.12 (d, J= 16.6, 2H)    
13
C NMR (CDCl3, 100MHz, δ ppm) 13.9, 15.4, 22.7, 25.8, 26.7, 29.2, 29.7, 31.6, 
51.34, 55.4, 65.8, 68.0, 109.9, 114.4, 115.3, 116.2, 126.8, 129.3, 129.8, 132.48, 
138.9, 141.0, 148.4, 160.0, 160.9  
 
2.2.6 Synthesis of 3-isothiocyanatoprop-1-yne (8) 
   
 
 
 
Figure 14. Synthesis of compound 8 
 
Propargyl amine (401.5 ml, 7.3 mmol) and triethyl amine (2216 mg, 21.9 mmol) 
was added to THF solution (10 ml) and the solution was cooled with an ice bath 
under Ar for 30 minutes. Then CS2 (556 mg, 7.3 mmol) was added to the reaction 
mixture dropwise over 30 minutes with vigorous stirring. After the addition was 
completed, the mixture was stirred at room temperature for 1 h. Then, the reaction 
mixture was cooled with an ice bath and TsCl (1540 mg, 8.103 mmol) was added 
and then stirred for half an hour at room temperature.  
At last, HCl (1N, 10ml) and diethylether (10ml) were added to the solution and 
extracted several times with small amount of diethyl ether. The organic phase was 
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dried with Na2SO4 and evaporated under reduced pressure. The purification was 
done by silica gel column by using hexane/chloroform mixture (10:1.5 v/v) as 
mobile phase. Fraction containing compound 8 was collected then the solvent was 
evaporated by rotary evaporator. The residual was yellow liquid with odor. (400 
mg, 4.1 mmol, %56) 
 
13
C NMR (CDCl3, 100MHz, δ ppm) 14.1, 31.6, 35.0, 73.8 
HRMS-ESI: calculated 97.00, found 96.9592 ∆m= 42 ppm 
 
2.2.7 Synthesis of Compound 9 (Click Reaction) 
 
 
Figure 15. Synthesis of compound 9 
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Synthesis was done following the procedure in literature
50
. Compound 7 (80 
mg, 0.093 mmol) and compound 8 (27 mg, 0.279 mmol) was dissolved in CHCl3 (6 
ml). A few drops of triethyl amine were added to the reaction and the mixture was 
stirred for 5 minutes at room temperature. In a vial, CuSO4 (5 mg) dissolved in 
water (0.7 ml). In another vial, sodium ascorbate (8 mg) was dissolved in water (0.7 
ml). CuSO4 and sodium ascorbate solutions were added to the reaction mixture in 
turn. The reaction mixture was stirred at room temperature for 48 h. Then the 
extraction was done with CHCl3 and water. Organic layer was dried with Na2SO4 
and evaporated under reduced pressure. The purification was done by silica gel 
column by using CHCl3 as mobile phase. Fraction was collected and the solvent was 
removed by using rotary evaporator. (20 mg, 0.021 mmol, 23%) 
1
H NMR (CDCl3, 400MHz, δ ppm) 1.30 (m, 4H), 1.50 (s, 6H), 1.85 (t, J= 7.9 Hz, 
2H), 2.05 (t, J= 7.5, 2H), 3.88 (s, 6H), 4.05 (t, J= 6.4, 2H), 4.43 (t, J= 7.2, 2H), 4.88 
(s, 2H), 6.82 (d, J= 8.8, 4H), 7.04 (d, J= 8.6, 2H), 7.19 (d, J= 8.6, 2H), 7.65 (m, 
2H+4H+1H), 8.14 (d, J= 16.6, 2H)    
 
13
C NMR (CDCl3, 100MHz, δ ppm) 14.0, 25.6, 26.6, 29.1, 29.8, 30.3, 41.1, 50.7, 
55.5, 67.9, 114.3,  115.3, 116.2, 121.6, 126.9, 128.8, 129.3, 129.7, 129.88, 130.93, 
132.5, 138.8, 141.0, 148.4, 160.0, 160.8 
MALDI: calculated 956.54 and found 956.16  
2.2.8 Synthesis of MSNs 
 
The synthesis was done according to the procedure in literature
53 
. 
Cetylammonium bromide (CTAB) (0.1g) was dissolved in NH4OH (50 g, 0.51 M) 
at 50
o
C and tetraethyl orthosilicate (TEOS) ( 0.8 ml, 0.2 M in ethanol) was added 
under continous stirring. After stirring 5 hours, 3-aminopropyltrimethoxysilane 
(APTMS) (0.8 ml of 12% (v/v) in ethanol) and TEOS (0.8 ml of 1M) were added to 
the solution and stirred for 1 hour. The solution was stirred for 24 hours at 50
o
C.  
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The solution was centrufuged and the precipitates were collected by washing 
with deionized water and ethanol several times. In order to remove surfactant 
templates particles were added to acidic ethanol (3 ml concentrate HCl in 100 ml of 
ethanol) and stirred 24 hours at 65
 o
C. 
2.2.9 Synthesis of PS-MSNs 
 
Compound 9 (10 mg) was added into distilled THF (6 ml). MSNs (60 mg) was 
added to the reaction mixture and the mixture was stirred for 2 days at room 
temperature. After 2 days, the mixture was centrufuged and washed with 
chloroform to get rid off the unreacted compound 9. This process was continued 
until there observed no color in the solution of centrufuged mixture.  
The solid particles were taken and were left to dry at room temperature.  
 
Figure 16. Schematic drawing of PS-MSNs 
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CHAPTER 3 
 
RESULTS AND DISCUSSION 
 
3.1 MSNs as a Carrier System for Photosensitizer 
 
 
Mesoporous silica nanoparticles are convenient carrier system for drugs when 
their unique properties such as; large surface areas, uniform pore sizes, 
hydrophilicity, acquiring targeting by surface modification and low cytotoxicity are 
considered. Photodynamic therapy, treatment of cancer cells by using 
photosensitizers along with light, growing interest of research recently. This way of 
therapy has numerous advantages over other types of cancer treatment. Since PDT 
maintains the treatment of tumors locally, it minimizes the damages to the 
surrounding healthy tissue. Photosensitizers tend to localize in cancer tissues more 
than the healthy tissues and the exposure of light to only cancer tissue provides 
further selectivity.  
3.1.1 Design of Photosensitizer 
 
In this study, we have designed a novel photodynamic therapy reagent based on 
BODIPY derivative where MSNs are used as carrier system. The reason for 
selecting BODIPY as photosensitizer is its stability under light, high extinction 
coefficient and ease of modification of its core. For instance, modification of 
BODIPY at 1,3,5,7 positions with styryl groups was reported by Akkaya et al. 
recently
35
. Here, we modified 3, 5 positions by Knoevenagel condensation reactions 
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and obtained distyryl-BODIPY. The aim of this modification was to move 
absorption and emission bands of the compund further into the red end of the 
visible spectrum.  
Bromination of the 2, 6 positions were done in order to increase spin-orbit 
coupling by introducing heavy atom. With this modification, transition from singlet 
excited state of photosensitizer to triplet state is enhanced
51
. In order to attach 
photosensitizer to mesoporous silica nanoparticles, isothiocyanate functional group 
was attached  to photosensitizer by click reaction. Characterization of all 
compounds were done by using 
1
H and 
13
C NMR spectra and Mass spectrometry 
analysis and are given in the appendices A and B.  
The absorbance maxima of the photosensitizer is at 653 nm which is convenient 
for photodynamic therapy since it is in the range of therapeutic window of body. 
(Figure 17.) The fluorescence emission maxima is at 678 nm (Figure 18.). 
Figure 17. Absorbance of compound 9 in CHCl3 
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Figure 18.  Fluorescense emission of compound 9 in CHCl3. Excitation is at 650 nm. 
 
3.1.2 Design of MSNs 
 
 
MSNs were sytnhesized with low-concentration of TEOS, CTAB as surfactant 
and base-catalyst NH4OH. In order to modify the surface of MSNs with 
photosensitizer, MSNs-APTS was synthesized. For this aim, sol gel process was 
applied by co-condensation of TEOS with APTS (3-aminopropyl-trimethoxy 
silane). The as synthesized particles were characterized by several characterization 
methods.  
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The size of the particles were measured as approximately 100 nm by using 
scanning electron microscopy (SEM). (Figure 19) 
 
 
 
Figure 19. SEM images of MSNs 
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Mesoporous surface of the particles can be seen in the images obtained by using 
transmission electron microscopy (TEM) (Figure 20.) 
 
   
 
Figure 20. TEM images of MSNs 
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X-ray diffraction characterization shows that MSNs have well-ordered lattice. 
The geometry of the lattice shows that MSNs have hexagonal unit cell. This type of 
MSNs is MCM-41. Because the parameters of the unit cell is just in order of few 
nanometers, the x-ray diffracted on small angles. (Figure. 21) 
 
  
Figure. 21 X-ray diffractogram of  MSN. 
 
The diffractogram shows four different well-resolved reflections. This shows its 
lattice has hexagonal structure.  
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In addition to SEM characterization, size measurements were done by using 
ZetaSizer. The measurement was repeated three times. According to these 
measurements %26 of the particles has the highest number of particles have the size 
of 122 nm in aqueous media. The polydispersity index of the particles were 0.5.  
(Figure. 22) 
 
 
Figure. 22 Size distribution of MSNs in water.  
 
Zeta potential measurements were obtained by using ZetaSizer. The zeta 
potential measurements of MSNs were obtained in water and repeated three times. 
As it can be seen in figure. 23 the mean value of potential is at 33 mV which is out 
of the range -30mV – 30mV. This indicates that the solvent in which MSNs were 
dispersed was not proper. As a result, water was not a proper solvent for MSNs, in 
time it would precipitate. (Figure. 23)    
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Figure. 23 Zeta potential distribution of MSNs 
 
 
Nitrogen adsorption (physisorption) analysis characterizes the texturel 
properties of materials such as surface area, pore size, pore volume and pore 
geometry.  The nitrogen isotherm of MCM-41 is shown in Figure 24. Both 
adsorption (black line) and desorption data (red line) are shown. As it can be seen in 
the graph, there are five districts. This isotherm is a typical MCM-41 isotherm. 
Accroding to BET analysis, the surface area of the particle is 1036 m
2
/g, pore 
volume is 1.678 cc/g, pore size is 3.082 nm. The outgas temperature was 150
o
C and 
the outgas time was 3 hours.  (Figure 24) 
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Figure 24. Nitrogen isotherm for all silica MCM-41. 
 
Singlet oxygen generation capability of photosensitizer attached MSN (PS- 
MSNs) was measured by observing photobleaching of trap molecule 1,3-
diphenylisobenzofuran (DPBF). 
1
O2 species that are generated by excited 
photosenstizer react with DPBF and the decrease in absorbance value of DPBF was 
observed by using UV-Vis-NIR Spectrophotometer.  
In order to observe singlet oxygen generation, we performed several number of 
experiments. First, the absorption of 0.67 mM DPBF solution was monitored after 
every 30 seconds of illumination by 660 nm LED light in every time. As shown in 
Figure. 24, there weren’t observed any decrease in absorption peak of DPBF. This 
result indicates that photobleaching did not occur.  
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Figure. 25 Absorbance of DPBF in isopropanol. Each measurement was done after  30 seconds 
of illumination.  
 
Second experiment was done in order to observe photobleaching of PS-MSNs. 
Measurements were done with 1 ml of PS-MSNs solution ( 8.2 mg PS-MSNs in 6 
mL isopropanol) in 3 ml of isopropanol. The measurement was performed every 
time after 30 seconds of illumination as done with DPBF before. And the result 
shows that the rate of photobleaching is very low for PS-MSNs. (Figure. 25) 
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Figure 26.  Absorbance spectra of PS-MSNs in isopropanol. Each measurement was done after  
30 seconds of illumination.  
 
Lastly, we performed the same measurement to observe singlet oxygen 
generation. 1ml PS-MSNs (8.2 mg PS-MSNs in 6 mL isopropanol), 0,5 ml DPBF 
(3 mM), 1.5 ml isopropanol was mixed together, 2 ml of the mixture was taken into 
1 ml of isopropanol and the measurements were done. Each measurement was taken 
after illuminated 30 seconds by 660 nm LED light. As shown in Figure 27, there 
observed a decrease in absorbance in every time that the solution was illuminated. 
This indicates that the photosenstizer can generate singlet oxygen efficiently when 
illuminated under light of 660 nm.  
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Figure 27. Bleaching of DPBF in the presence of PS-MSNs.  
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CHAPTER 4 
 
CONCLUSION 
 
 
In this study, novel BODIPY-based photodynamic therapy reagent and a carrier 
system were designed, synthesized and characterized. We studied to modify 
BODIPY dye to attach MSNs covalently. The photosenstizer has a 653 nm 
absorption maxima which makes it a good candidate to be used in PDT. 
We synthesized MCM-41 type MSNs in order to use as drug carrier system. We 
used the instruments SEM, TEM, XRD, ZetaSizer in order to characterize MSNs. 
Since MSNs have amine groups on surface, it is easy to modify them in order to 
enhance targeting.  
Singlet oxygen generation experiments show that the compound 9 is a good 
singlet oxygen generator and the carrier system does not influence the efficiency of 
singlet oxygen generation.  
In conclusion, we have demonstrated that for PDT, MSNs can be used in the 
delivery of PS with the low toxicity, uniform pores, easily modified surface of 
MSNs and BODIPY dyes are good PSs  with the efficent singlet oxygen generation. 
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APPENDİX A 
 
Figure 28. 
1
H NMR of compound 3  
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Figure 29. 
1
H NMR of compound 4 
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Figure 30. 
1
H NMR of compound 5  
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Figure 31. 
1
H NMR of compound 6  
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Figure 32. 
1
H NMR of compound 7  
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Figure 33. 
1
H NMR of compound 9  
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Figure 34. 
1
H NMR of compound 9 (aromatic region)  
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Figure 35.  
13
C NMR of compound 5 
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Figure 36. 
13
C NMR of compound 6 
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Figure 37.  
13
C NMR of compound 7 
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Figure 38. 
13
C NMR of compound 8 
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Figure 39. 13C NMR of compound 9 
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Figure 40.  ESI-HRMS of compound 5 
 
 
 
 
 
Figure 41. ESI-HRMS of compound 6 
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Figure 42. ESI-HRMS of compound 8 
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Figur 43. MALDI-MS of compound 9 
